Silver Book Fact

In a study of different treatments for Parkinson’s disease, results showed that the disease can be managed for up to 5 years with a reduces risk of dyskinesia.

Rascol, Olivier, David J. Brooks, Amos D. Korczyn, Peter P. DeDeyn, Carl E. Clarke, and Anthony E. Lang, for The 056 Study Group. A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson’s Disease Who Were Treated with Ropinirole or Levodopa. N Engl J Med. 2000; 342(20): 1484-91. http://content.nejm.org/cgi/content/abstract/342/20/1484

Reference

Title
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson’s Disease Who Were Treated with Ropinirole or Levodopa
Publication
N Engl J Med
Publication Date
2000
Authors
Rascol, Olivier, David J. Brooks, Amos D. Korczyn, Peter P. DeDeyn, Carl E. Clarke, and Anthony E. Lang, for The 056 Study Group
Volume & Issue
Volume 342, Issue 20
Pages
1484-91
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • In one study, deep-brain stimulation for Parkinson’s patients significantly reduced their required dosages of antiparkinsonian medications, consequently decreasing their medication costs by 32% 1 year after surgery, and 39% 2…  
  • Around 75 – 100 experimental therapies that are aimed at slowing or stopping the progression of Alzheimer’s disease are currently in clinical trials.  
  • Medicaid Costs, Slowed Progression  
  • Slowing the Progress of Parkinson’s Disease Would Save Money
     
  • The U.S. Food and Drug Administration has approved 5 drugs for the treatment of Alzheimer’s disease. These drugs have been found to temporarily slow the worsening of Alzheimer’s symptoms for…